The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Lomitapide and Mipomersen: Two First-in-Class Drugs for Reducing Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial
Huijgen, R., Boekholdt, S. M., Arsenault, B. J., Bao, W., Davaine, J., Tabet, F., Petrides, F., Rye, K., DeMicco, D. A., Barter, P. J., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.043 · Cited by 56
Self-citationRetractedThe metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Absence of Microsomal Triglyceride Transfer Protein in Individuals with Abetalipoproteinemia
Wetterau, J. R., Aggerbeck, L. P., Bouma, M.-E., Eisenberg, C., Munck, A., Hermier, M., Schmitz, J., Gay, G., Rader, D. J., & Gregg, R. E. (1992) · Science · doi:10.1126/science.1439810 · Cited by 762
Self-citationCuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744
Self-citationSniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659
Cited by
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Raal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
Gidding, S. S., Ann Champagne, M., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., McCrindle, B., Raal, F., Rader, D., Santos, R. D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000297 · Cited by 723
Self-citationDuell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Clinical Genetic Testing for Familial Hypercholesterolemia
Sturm, A. C., Knowles, J. W., Gidding, S. S., Ahmad, Z. S., Ahmed, C. D., Ballantyne, C. M., Baum, S. J., Bourbon, M., Carrié, A., Cuchel, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.044 · Cited by 615
Self-citationTherapeutic Targeting of Long Non-Coding RNAs in Cancer
Arun, G., Diermeier, S. D., & Spector, D. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.01.001 · Cited by 611
Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M. B., Orringer, C. E., & Smith, S. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.519 · Cited by 459
2016 Chinese guidelines for the management of dyslipidemia in adults.
(2018) · PubMed · doi:10.11909/j.issn.1671-5411.2018.01.011 · Cited by 457
Pharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N., Swayze, E., & Geary, R. S. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 425
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M. B., Orringer, C. E., & Smith, S. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.745 · Cited by 377
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356
ANGPTL3 inhibition in homozygous familial hypercholesterolemia
Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
New insights into the regulation of chylomicron production
Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194
Fogacci, F., Ferri, N., Toth, P. P., Ruscica, M., Corsini, A., & Cicero, A. F. G. (2019) · Drugs · doi:10.1007/s40265-019-01114-z · Cited by 132
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Mipomersen and its use in familial hypercholesterolemia
Parham, J. S., & Goldberg, A. C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1550071 · Cited by 94
Generation of human adult hepatocyte organoids with metabolic functions
Igarashi, R., Oda, M., Okada, R., Yano, T., Takahashi, S., Pastuhov, S., Matano, M., Masuda, N., Togasaki, K., Ohta, Y., et al. (2025) · Nature · doi:10.1038/s41586-025-08861-y · Cited by 85
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
“Thus, lomitapide, an oral microsomal triglyceride transfer protein inhibitor, reduces LDL cholesterol by 35 to 50% in subjects with homozygous FH.84,85 Lomitapide has Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval for the treatment of homozygous FH as an adjunct to diet and drug therap…”
BackgroundInfluentialSelf-citationPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.766 · Cited by 59
Somanathan, S., Jacobs, F., Wang, Q., Hanlon, A. L., Wilson, J. M., & Rader, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.115.304008 · Cited by 54
Self-citationSusan-Resiga, D., Girard, E., Kiss, R. S., Essalmani, R., Hamelin, J., Asselin, M.-C., Awan, Z., Butkinaree, C., Fleury, A., Soldera, A., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.769430 · Cited by 35
Hepatic SREBP signaling requires SPRING to govern systemic lipid metabolism in mice and humans
Hendrix, S., Kingma, J., Ottenhoff, R., Valiloo, M., Svecla, M., Zijlstra, L. F., Sachdev, V., Kovac, K., Levels, J. H. M., Jongejan, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40943-1 · Cited by 34
Agarwala, A., Jones, P., & Nambi, V. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0467-4 · Cited by 31
Goulooze, S. C., Cohen, A. F., & Rissmann, R. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12612 · Cited by 29
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Metadata
- Authors
- Rader, D. J., & Kastelein, J. J. P.
- Venue
- Circulation
- Published
- 2014-03-04
- Volume
- 129
- Issue
- 9
- Pages
- 1022-1032
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2064387909
- Cited by
- 264
- References
- 80
- FWCI
- 35.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.